Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese

(2012) Motohiro Yamamori et al.   International Journal of Medical Sciences

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

(2010) A Abajo et al.   BRITISH JOURNAL OF CANCER

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

(2010) Vincenzo Formica et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

(2010) T F Hansen et al.   PHARMACOGENOMICS JOURNAL

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

(2009) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors

(2009) L. Jain et al.   MOLECULAR CANCER THERAPEUTICS

Discordant somatic and germlineVEGF-Agenotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

(2009) Luigi Coltelli et al.   PHARMACOGENOMICS

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

(2008) A. M. Schultheis et al.   CLINICAL CANCER RESEARCH

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

(2008) H. J. Burstein et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer

(2008) J. G. Kim et al.   CLINICAL CANCER RESEARCH

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE